Snapshot from Jun 26, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / International AIDS Vaccine Initiative / Merck & Co.

International AIDS Vaccine Initiative & Merck & Co.

2 shared events · Importance 3 · Last updated Jun 03, 2026

Importance
3
Shared Events
2
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
Shared Events (2)
42
Tech
CEPI Funds Ebola Bundibugyo Vaccine Development
International AIDS Vaccine Initiative: The International AIDS Vaccine Initiative (IAVI) received an initial $3.2 million from CEPI to develop a single-dose Bundibugyo vaccine candidate using technology similar to Merck's Ervebo.
Merck & Co.: Merck & Co.'s approved vaccine Ervebo for the Zaire strain of Ebola is referenced as a technological precedent for IAVI's Bundibugyo vaccine candidate.
May 22, 2026 · 36 articles
30
Accidents
Unknown Event
International AIDS Vaccine Initiative: The International AIDS Vaccine Initiative is developing a Bundibugyo-specific version of a vaccine using a platform similar to Merck & Co.'s Ervebo vaccine, contributing to the search for a treatment.
Merck & Co.: Merck & Co.>>>'s Ervebo vaccine, effective against the Zaire strain of Ebola, is being considered for potential use against the Uganda — Bundibugyo strain, though its efficacy is still under assessment.
May 18, 2026 · 505 articles
NEWSDESK
Explore this relationship live

Track how International AIDS Vaccine Initiative and Merck & Co. interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.